You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 5, 2024

OPFOLDA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Opfolda patents expire, and what generic alternatives are available?

Opfolda is a drug marketed by Amicus Therap Us and is included in one NDA. There are seven patents protecting this drug.

This drug has one hundred and thirty-seven patent family members in forty-one countries.

The generic ingredient in OPFOLDA is miglustat. There are two drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the miglustat profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Opfolda

A generic version of OPFOLDA was approved as miglustat by ANI PHARMS on April 17th, 2018.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for OPFOLDA?
  • What are the global sales for OPFOLDA?
  • What is Average Wholesale Price for OPFOLDA?
Summary for OPFOLDA
International Patents:137
US Patents:7
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Drug Prices: Drug price information for OPFOLDA
What excipients (inactive ingredients) are in OPFOLDA?OPFOLDA excipients list
DailyMed Link:OPFOLDA at DailyMed
Drug patent expirations by year for OPFOLDA
Drug Prices for OPFOLDA

See drug prices for OPFOLDA

US Patents and Regulatory Information for OPFOLDA

OPFOLDA is protected by seven US patents and one FDA Regulatory Exclusivity.

Patents protecting OPFOLDA

Highly potent acid alpha-glucosidase with enhanced carbohydrates
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: THE TREATMENT OF POMPE PATIENTS

High concentration alpha-glucosidase compositions for the treatment of pompe disease
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: THE TREATMENT OF POMPE PATIENTS

Augmented acid alpha-glucosidase for the treatment of Pompe disease
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: THE TREATMENT OF POMPE PATIENTS

Highly potent acid alpha-glucosidase with enhanced carbohydrates
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: THE TREATMENT OF POMPE PATIENTS

High concentration alpha-glucosidase compositions for the treatment of Pompe disease
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: THE TREATMENT OF POMPE PATIENTS

Augmented acid alpha-glucosidase for the treatment of Pompe disease
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: THE TREATMENT OF POMPE PATIENTS


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: THE TREATMENT OF POMPE PATIENTS

FDA Regulatory Exclusivity protecting OPFOLDA

NEW PRODUCT
Exclusivity Expiration: ⤷  Sign Up

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Amicus Therap Us OPFOLDA miglustat CAPSULE;ORAL 215211-001 Sep 28, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Amicus Therap Us OPFOLDA miglustat CAPSULE;ORAL 215211-001 Sep 28, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
Amicus Therap Us OPFOLDA miglustat CAPSULE;ORAL 215211-001 Sep 28, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Amicus Therap Us OPFOLDA miglustat CAPSULE;ORAL 215211-001 Sep 28, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for OPFOLDA

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Piramal Critical Care B.V. Yargesa miglustat EMEA/H/C/004016
Yargesa is indicated for the oral treatment of adult patients with mild to moderate type 1 Gaucher disease.Yargesa may be used only in the treatment of patients for whom enzyme replacement therapy is unsuitable.Yargesa is indicated for the treatment of progressive neurological manifestations in adult patients and paediatric patients with Niemann-Pick type C disease.
Authorised yes no no 2017-03-22
Janssen Cilag International NV Zavesca miglustat EMEA/H/C/000435
Zavesca is indicated for the oral treatment of adult patients with mild to moderate type-1 Gaucher disease. Zavesca may be used only in the treatment of patients for whom enzyme replacement therapy is unsuitable.Zavesca is indicated for the treatment of progressive neurological manifestations in adult patients and paediatric patients with Niemann-Pick type-C disease.
Authorised no no no 2002-11-20 2009-06-16
Gen.Orph Miglustat Gen.Orph miglustat EMEA/H/C/004366
Miglustat Gen.Orph is indicated for the oral treatment of adult patients with mild to moderate type 1 Gaucher disease. Miglustat Gen.Orph may be used only in the treatment of patients for whom enzyme replacement therapy is unsuitable.Miglustat Gen.Orph is indicated for the treatment of progressive neurological manifestations in adult patients and paediatric patients with Niemann-Pick type C disease.
Authorised yes no no 2017-11-09
Dipharma Arzneimittel GmbH Miglustat Dipharma miglustat EMEA/H/C/004904
Miglustat Dipharma is indicated for the oral treatment of adult patients with mild to moderate type 1 Gaucher disease.Miglustat Dipharma may be used only in the treatment of patients for whom enzyme replacement therapy is unsuitable.Miglustat Dipharma is indicated for the treatment of progressive neurological manifestations in adult patients and paediatric patients with Niemann-Pick type C disease.
Authorised yes no no 2019-02-18
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for OPFOLDA

See the table below for patents covering OPFOLDA around the world.

Country Patent Number Title Estimated Expiration
Japan 2015509542 ポンペ病の処置のための高濃度α−グルコシダーゼ組成物 ⤷  Sign Up
Taiwan I843172 ⤷  Sign Up
Spain 2967620 ⤷  Sign Up
Taiwan 201726163 Augmented acid alpha-glucosidase for the treatment of pompe disease ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for OPFOLDA

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
3201320 LUC00336 Luxembourg ⤷  Sign Up PRODUCT NAME: CIPAGLUCOSIDASE ALFA; AUTHORISATION NUMBER AND DATE: EU/1/22/1714 20230324
3201320 CA 2024 00012 Denmark ⤷  Sign Up PRODUCT NAME: CIPAGLUCOSIDASE ALFA; REG. NO/DATE: EU/1/22/1714 20230324
3201320 122024000016 Germany ⤷  Sign Up PRODUCT NAME: CIPAGLUCOSIDASE ALFA; REGISTRATION NO/DATE: EU/1/22/1714 20230320
3201320 PA2024509 Lithuania ⤷  Sign Up PRODUCT NAME: CIPAGLIUKOZIDAZE ALFA; REGISTRATION NO/DATE: EU/1/22/1714 20230320
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.